Novel inhibitors of poly(ADP-ribose) synthetase
- PMID: 6248035
- PMCID: PMC1161458
- DOI: 10.1042/bj1850775
Novel inhibitors of poly(ADP-ribose) synthetase
Abstract
In a search for new inhibitors of the nuclear enzyme poly(ADP-ribose) synthetase, it was found that various benzamides substituted in the 3-position were the most inhibitory compounds found to date. Two of the benzamides, 3-aminobenzamide and 3-methoxybenzamide, were found to be competitive inhibitors, with Ki values or less than 2 microM.
Similar articles
-
Induction of murine teratocarcinoma cell differentiation by suppression of poly(ADP-ribose) synthesis.Proc Natl Acad Sci U S A. 1984 Nov;81(22):7132-6. doi: 10.1073/pnas.81.22.7132. Proc Natl Acad Sci U S A. 1984. PMID: 6095269 Free PMC article.
-
Effect of poly(ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis.Diabetes. 1983 Apr;32(4):316-8. doi: 10.2337/diab.32.4.316. Diabetes. 1983. PMID: 6299867
-
Inhibitors of poly(ADP-ribose) polymerase enhance unscheduled DNA synthesis in human peripheral lymphocytes.Biochem Biophys Res Commun. 1981 May 15;100(1):463-70. doi: 10.1016/s0006-291x(81)80119-2. Biochem Biophys Res Commun. 1981. PMID: 6266408 No abstract available.
-
Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Evidence of islet B-cell regeneration.Diabetes. 1984 Apr;33(4):401-4. doi: 10.2337/diab.33.4.401. Diabetes. 1984. PMID: 6323238
-
Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo.J Biol Chem. 1989 Mar 15;264(8):4312-7. J Biol Chem. 1989. PMID: 2538435
Cited by
-
Lymphocyte dysfunction after DNA damage by toxic oxygen species. A model of immunodeficiency.J Exp Med. 1986 Mar 1;163(3):746-51. doi: 10.1084/jem.163.3.746. J Exp Med. 1986. PMID: 3950545 Free PMC article.
-
Inhibitors of PARP: Number crunching and structure gazing.Proc Natl Acad Sci U S A. 2022 Mar 15;119(11):e2121979119. doi: 10.1073/pnas.2121979119. Epub 2022 Mar 8. Proc Natl Acad Sci U S A. 2022. PMID: 35259019 Free PMC article.
-
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues.Cancer Drug Resist. 2019 Sep 19;2(3):665-679. doi: 10.20517/cdr.2019.002. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582575 Free PMC article. Review.
-
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.Cancers (Basel). 2020 Feb 29;12(3):564. doi: 10.3390/cancers12030564. Cancers (Basel). 2020. PMID: 32121331 Free PMC article. Review.
-
Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Drug Des Devel Ther. 2018 May 29;12:1501-1509. doi: 10.2147/DDDT.S124447. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29881257 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources